Chromatrap, a business unit of Porvair Sciences, has announced that it will be the lead sponsor at the Epigenetics in Drug Discovery conference to be held in Cambridge from 26-27 January
Understanding epigenetic mechanisms in both new and existing drugs is enabling the discovery of novel drugs according to Chromatrap.
At the conference Amy Beynon will deliver a presentation highlighting the use of Chromatrap’s solid state ChIP technology for assaying methylated and hydroxymethylated DNA marks in addition to Histone modifications and the use of Chromatrap kits for ChIP-sequencing.
To register for the Epigenetics in Drug Discovery conference, click here.